Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: song k. Blood Cancer J. 2023 Aug 28;13(1):129. doi: 10.1038/s41408-023-00888-6. Blood Cancer J. 2023. PMID: 37635183 Free PMC article. No abstract available.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM. Stewart AK, et al. Among authors: song k. Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7. Blood. 2013. PMID: 23297129 Free PMC article. Clinical Trial.
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. Han M, et al. Among authors: song k. Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. Blood. 2016. PMID: 27338095 Free article. No abstract available.
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Talamo G, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Reece D, Pierceall WE, Chung W, Zafar F, Agarwal A, Bahlis NJ. Siegel DS, et al. Among authors: song k. Leukemia. 2020 Dec;34(12):3286-3297. doi: 10.1038/s41375-020-0813-1. Epub 2020 May 6. Leukemia. 2020. PMID: 32376855 Free PMC article. Clinical Trial.
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Belch A, Bahlis N, White D, Cheung M, Chen C, Shustik C, Song K, Tosikyan A, Dispenzieri A, Anderson K, Brown D, Robinson S, Srinivasan S, Facon T. Belch A, et al. Among authors: song k. Cancer Med. 2020 Dec;9(23):8923-8930. doi: 10.1002/cam4.3511. Epub 2020 Oct 13. Cancer Med. 2020. PMID: 33049118 Free PMC article. Clinical Trial.
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Aslam M, Louzada M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: song k. Haematologica. 2021 Jun 1;106(6):1733-1736. doi: 10.3324/haematol.2020.259093. Haematologica. 2021. PMID: 33054120 Free PMC article. No abstract available.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Louzada M, Aslam M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: song k. Eur J Haematol. 2021 May;106(5):673-681. doi: 10.1111/ejh.13596. Epub 2021 Feb 16. Eur J Haematol. 2021. PMID: 33539037
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH, Venner C, McCurdy A, Masih-Khan E, Atenafu EG, Sebag M, Stakiw J, Song K, LeBlanc R, Reiman T, Louzada M, Kotb R, Gul E, Reece D. Jimenez-Zepeda VH, et al. Among authors: song k. Br J Haematol. 2021 May;193(3):532-541. doi: 10.1111/bjh.17350. Epub 2021 Feb 9. Br J Haematol. 2021. PMID: 33559897 Clinical Trial.
8,147 results